Drug-resistant mutation patterns in CRF01_AE cases that failed d4T+3TC+nevirapine fixed-dosed, combination treatment: Follow-up study from the Lampang cohort

Antiviral Research

Volumn 87, Issue 1, 2010, Pages 22-29

  Saeng aroon, Siriphan ^a   Tsuchiya, Naho ^b   Auwanit, Wattana ^a   Ayuthaya, Panasda Isarangura Na ^a   Pathipvanich, Panita ^c   Sawanpanyalert, Pathom ^a   Rojanawiwat, Archawin ^a   Kannagi, Mari ^d   Ariyoshi, Koya ^b   Sugiura, Wataru ^e,f,g  

^a MINISTRY OF PUBLIC HEALTH   (Thailand)

^b NAGASAKI UNIVERSITY   (Japan)

^c LAMPANG HOSPITAL   (Thailand)

^d TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^e NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^f NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

^g NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Connection domain; CRF01_AE; Drug resistance; GPOvir; Polymorphism; RNase H

Indexed keywords

DIDANOSINE; INDINAVIR; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; RIBONUCLEASE; RITONAVIR; ZALCITABINE; ZIDOVUDINE;

ADULT; AMINO ACID SEQUENCE; ANTIVIRAL RESISTANCE; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG TREATMENT FAILURE; FEMALE; FOLLOW UP; GENE MUTATION; GENETIC POLYMORPHISM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DOMAIN; THAILAND; UNINDEXED SEQUENCE;

ADULT; AMINO ACID SUBSTITUTION; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG RESISTANCE, VIRAL; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV-1; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; MUTATION, MISSENSE; NEVIRAPINE; POLYMORPHISM, GENETIC; SEQUENCE ANALYSIS, DNA; STAVUDINE; THAILAND; TREATMENT FAILURE;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 77953519153     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2010.04.001     Document Type: Article

References (43)

1. Arts E.J., Quiñones-Mateu M.E., Albright J.L., Marois J.P., Hough C., Gu Z., Wainberg M.A. 3'-Azido-3'-deoxythymidine (AZT) mediates cross-resistance to nucleoside analogs in the case of AZT-resistant human immunodeficiency virus type 1 variants. J. Virol. 1998, 72:4858-4865.
2. Boyer P.L., Sarafianos S.G., Clark P.K., Arnold E., Hughes S.H. Why do HIV-1 and HIV-2 use different pathways to develop AZT resistance?. PLoS Pathog. 2006, 2:e10.
3. Brehm J.H., Koontz D., Meteer J.D., Pathak V., Sluis-Cremer N., Mellors J.W. Selection of mutations in the connection and RNase H domains of human immunodeficiency virus type 1 reverse transcriptase that increase resistance to 3'-azido-3'-dideoxythymidine. J. Virol. 2007, 81:7852-7859.
4. Brenner B., Turner D., Oliveira M., Moisi D., Detorio M., Carobene M., Marlink R.G., Schapiro J., Roger M., Wainberg M.A. A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors. AIDS 2003, 17:F1-5.
5. Chetchotisakd P., Anunnatsiri S., Kiertiburanakul S., Sutthent R., Anekthananon T., Bowonwatanuwong C., Kowadisaiburana B., Supparatpinyo K., Horsakulthai M., Chasombat S., Ruxrungtham K. High rate multiple drug resistances in HIV-infected patients failing nonnucleoside reverse transcriptase inhibitor regimens in Thailand, where subtype A/E is predominant. J. Int. Assoc. Physicians AIDS Care (Chic Ill) 2006, 5:152-156.
6. Clavel F., Hance A.J. HIV drug resistance. N. Engl. J. Med. 2004, 350:1023-1035.
7. Delviks-Frankenberry K.A., Nikolenko G.N., Barr R., Pathak V.K. Mutations in human immunodeficiency virus type 1 RNase H primer grip enhance 3'-azido-3'-deoxythymidine resistance. J. Virol. 2007, 81:6837-6845.
8. Deshpande A., Jauvin V., Magnin N., Pinson P., Faure M., Masquelier B., Aurillac-Lavignolle V., Fleury H.J. Resistance mutations in subtype C HIV type 1 isolates from Indian patients of Mumbai receiving NRTIs plus NNRTIs and experiencing a treatment failure: resistance to AR. AIDS Res. Hum. Retroviruses 2007, 23:335-340.
9. Ehteshami M., Beilhartz G.L., Scarth B.J., Tchesnokov E.P., McCormick S., Wynhoven B., Harrigan P.R., Götte M. Connection domain mutations N348I and A360V in HIV-1 reverse transcriptase enhance resistance to 3'-azido-3'-deoxythymidine through both RNase H-dependent and -independent mechanisms. J. Biol. Chem. 2008, 283:22222-22232.
10. Gonzales M.J., Wu T.D., Taylor J., Belitskaya I., Kantor R., Israelski D., Chou S., Zolopa A.R., Fessel W.J., Shafer R.W. Extended spectrum of HIV-1 reverse transcriptase mutations in patients receiving multiple nucleoside analog inhibitors. AIDS 2003, 17:791-799.
11. Grossman Z., Istomin V., Averbuch D., Lorber M., Risenberg K., Levi I., Chowers M., Burke M., Bar Yaacov N., Schapiro J.M. Genetic variation at NNRTI resistance-associated positions in patients infected with HIV-1 subtype C. AIDS 2004, 18:909-915.
12. Hachiya A., Kodama E.N., Sarafianos S.G., Schuckmann M.M., Sakagami Y., Matsuoka M., Takiguchi M., Gatanaga H., Oka S. Amino acid mutation N348I in the connection subdomain of human immunodeficiency virus type 1 reverse transcriptase confers multiclass resistance to nucleoside and nonnucleoside reverse transcriptase inhibitors. J. Virol. 2008, 82:3261-3270.
13. Hirsch M.S., Brun-Vézinet F., Clotet B., Conway B., Kuritzkes D.R., D'Aquila R.T., Demeter L.M., Hammer S.M., Johnson V.A., Loveday C., Mellors J.W., Jacobsen D.M., Richman D.D. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. Clin. Infect. Dis. 2003, 37:113-128.
14. Johnson V.A., Brun-Vezinet F., Clotet B., Gunthard H.F., Kuritzkes D.R., Pillay D., Schapiro J.M., Richman D.D. Update of the Drug Resistance Mutations in HIV-1. Top. HIV Med. 2008, 16:138-145.
15. Julias J.G., McWilliams M.J., Sarafianos S.G., Alvord W.G., Arnold E., Hughes S.H. Mutation of amino acids in the connection domain of human immunodeficiency virus type 1 reverse transcriptase that contact the template-primer affects RNase H activity. J. Virol. 2003, 77:8548-8554.
16. Kantor R., Katzenstein D. Polymorphism in HIV-1 non-subtype B protease and reverse transcriptase and its potential impact on drug susceptibility and drug resistance evolution. AIDS Rev. 2003, 5:25-35.
17. Kimura M. Estimation of evolutionary distances between homologous nucleotide sequences. Proc. Natl. Acad. Sci. U.S.A. 1981, 78:454-458.
18. Kumarasamy N., Solomon S., Chaguturu S.K., Mahajan A.P., Flanigan T.P., Balakrishnan P., Mayer K.H. The safety, tolerability and effectiveness of generic antiretroviral drug regimens for HIV-infected patients in south India. AIDS 2003, 17:2267-2269.
19. Lacey S.F., Larder B.A. Novel mutation (V75T) in human immunodeficiency virus type 1 reverse transcriptase confers resistance to 2',3'-didehydro-2',3'-dideoxythymidine in cell culture. Antimicrob. Agents Chemother. 1994, 38:1428-1432.
20. Lennerstrand J., Hertogs K., Stammers D.K., Larder B.A. Correlation between viral resistance to zidovudine and resistance at the reverse transcriptase level for a panel of human immunodeficiency virus type 1 mutants. J. Virol. 2001, 75:7202-7205.
21. Lennerstrand J., Stammers D.K., Larder B.A. Biochemical mechanism of human immunodeficiency virus type 1 reverse transcriptase resistance to stavudine. Antimicrob. Agents Chemother. 2001, 45:2144-2146.
22. Liu L., Lu H.Z., Henry M., Tamalet C. Polymorphism and drug selected mutations of reverse transcriptase gene in 102 HIV-1 infected patients living in China. J. Med. Virol. 2007, 79:1593-1599.
23. Loemba H., Brenner B., Parniak M.A., Ma'ayan S., Spira B., Moisi D., Oliveira M., Detorio M., Wainberg M.A. Genetic divergence of human immunodeficiency virus type 1 Ethiopian clade C reverse transcriptase (RT) and rapid development of resistance against nonnucleoside inhibitors of RT. Antimicrob. Agents Chemother. 2002, 46:2087-2094.
24. Ministry of Public Health, 2008. The Asian Epidemic Model (AEM) Projections for HIV/AIDS in Thailand: 2005-2025.
25. Myint L., Ariyoshi K., Yan H., Frater A.J., Auwanit W., Pathipvanith P., Yamada K., Matsuda M., Chiba T., Fujita K., McClure M., Weber J.N., Sugiura W. Mutagenically separated PCR assay for rapid detection of M41L and K70R zidovudine resistance mutations in CRF01_AE (Subtype E) human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 2002, 46:3861-3868.
26. Nikolenko G.N., Delviks-Frankenberry K.A., Palmer S., Maldarelli F., Fivash M.J., Coffin J.M., Pathak V.K. Mutations in the connection domain of HIV-1 reverse transcriptase increase 3'-azido-3'-deoxythymidine resistance. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:317-322.
27. Ntemgwa M., Wainberg M.A., Oliveira M., Moisi D., Lalonde R., Micheli V., Brenner B.G. Variations in reverse transcriptase and RNase H domain mutations in human immunodeficiency virus type 1 clinical isolates are associated with divergent phenotypic resistance to zidovudine. Antimicrob. Agents Chemother. 2007, 51:3861-3869.
28. Parikh U.M., Bacheler L., Koontz D., Mellors J.W. The K65R mutation in human immunodeficiency virus type 1 reverse transcriptase exhibits bidirectional phenotypic antagonism with thymidine analog mutations. J. Virol. 2006, 80:4971-4977.
29. Perach M., Rubinek T., Hughes S.H., Hizi A. Analysis of HIV-2 RT mutants provides evidence that resistance of HIV-1 RT and HIV-2 RT to nucleoside analogs involves a repositioning of the template-primer. J. Mol. Biol. 1997, 268:648-654.
30. Poveda E., de Mendoza C., Pattery T., González Mdel M., Villacian J., Soriano V. Phenotypic impact of resistance mutations on etravirine susceptibility in HIV patients with prior failure to nonnucleoside analogues. AIDS 2008, 22:2395-2398.
31. Pujari S.N., Patel A.K., Naik E., Patel K.K., Dravid A., Patel J.K., Mane A.A., Bhagat S. Effectiveness of generic fixed-dose combinations of highly active antiretroviral therapy for treatment of HIV infection in India. J. Acquir. Immune Defic. Syndr. 2004, 37:1566-1569.
32. Quan Y., Gu Z., Li X., Liang C., Parniak M.A., Wainberg M.A. Endogenous reverse transcriptase assays reveal synergy between combinations of the M184V and other drug resistance-conferring mutations in interactions with nucleoside analog triphosphates. J. Mol. Biol. 1998, 277:237-247.
33. Saeng-Aroon S., Yoshida L.M., Ariyoshi K., Taguchi M., Pathipvanich P., Rojanawiwat A., Matsuda M., Kannagi M., Sawanpanyalert P., Sugiura W., Auwanit W. An efficient tool for surveying CRF01_AE HIV type 1 resistance in Thailand to combined stavudine-lamivudine-nevirapine treatment: mutagenically separated PCR targeting M184I/V. AIDS Res. Hum. Retroviruses 2007, 23:1461-1468.
34. Santos A.F., Lengruber R.B., Soares E.A., Jere A., Sprinz E., Martinez A.M., Silveira J., Sion F.S., Pathak V.K., Soares M.A. Conservation patterns of HIV-1 RT connection and RNase H domains: identification of new mutations in NRTI-treated patients. PLoS One 2008, 3:e1781.
35. Sungkanuparph S., Manosuthi W., Kiertiburanakul S., Piyavong B., Chumpathat N., Chantratita W. Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails. Clin. Infect. Dis. 2007, 44:447-452.
36. Sungkanuparph S., Manosuthi W., Kiertiburanakul S., Saekang N., Pairoj W., Chantratita W. Prevalence and risk factors for developing K65R mutations among HIV-1 infected patients who fail an initial regimen of fixed-dose combination of stavudine, lamivudine, and nevirapine. J. Clin. Virol. 2008, 41:310-313.
37. Tamura K., Dudley J., Nei M., Kumar S. MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. Mol. Biol. Evol. 2007, 24:1596-1599.
38. Tsuchiya N., Pathipvanich P., Yasuda T., Mukoyama Y., Rojanawiwat A., Matsubayashi T., Saeng-aroon S., Auwanit W., Matsuyama A., Sawanpanyalert P., Ariyoshi K. Demographic, socio-economic, behavioral and clinical factors predicting virologic failure with generic fixed-dose combination antiretroviral therapy before universal health insurance coverage in northern Thailand. Southeast Asian J. Trop. Med. Public Health 2009, 40:71-82.
39. Waters J.M., O'Neal W., White K.L., Wakeford C., Lansdon E.B., Harris J., Svarovskaia E.S., Miller M.D., Borroto-Esoda K. Mutations in the thumb-connection and RNase H domain of HIV type-1 reverse transcriptase of antiretroviral treatment-experienced patients. Antivir. Ther. 2009, 14:231-239.
40. WHO, 2003. Scaling up antiretroviral therapy in resource-limited settings: treatment guidelines for a public helath approach.
41. Yap S.H., Sheen C.W., Fahey J., Zanin M., Tyssen D., Lima V.D., Wynhoven B., Kuiper M., Sluis-Cremer N., Harrigan P.R., Tachedjian G. N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance. PLoS Med. 2007, 4:e335.
42. Zelina S., Sheen C.W., Radzio J., Mellors J.W., Sluis-Cremer N. Mechanisms by which the G333D mutation in human immunodeficiency virus type 1 Reverse transcriptase facilitates dual resistance to zidovudine and lamivudine. Antimicrob. Agents Chemother. 2008, 52:157-163.
43. Zhou J., Paton N.I., Ditangco R., Chen Y.M., Kamarulzaman A., Kumarasamy N., Lee C.K., Li P.C., Merati T.P., Phanuphak P., Pujari S., Vibhagool A., Zhang F., Chuah J., Frost K.R., Cooper D.A., Law M.G. Experience with the use of a first-line regimen of stavudine, lamivudine and nevirapine in patients in the TREAT Asia HIV Observational Database. HIV Med. 2007, 8:8-16.